Rapid Acceleration for Diagnostics in Underserved Populations: Home Testing (SYCT)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
North Carolina
-
Greenville, North Carolina, United States, 27705
- Greenville Pitt County
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37341
- Hamilton County
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Self-reported primary residence within the pre-identified communities
- Age> 8 years at enrollment
- Provision of signed and dated informed consent form
Exclusion Criteria: None if above are met
-
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
People who use the self administered SARs-CoV-2 antigen testing kits
|
Behavioral surveys and questionaires
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants Who Reported Not Following Social Distancing Guidelines
Time Frame: 2 weeks
|
Number of participants who reported at their first follow-up assessment as having close contact (within 6 feet) with people who do not live with them.
|
2 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants That Avoided Public Spaces, Gatherings, or Crowds as a Prevention Measure
Time Frame: 2 weeks
|
Number of participants who reported at their first follow-up assessment as having avoided public spaces, gatherings, or crowds as a prevention measure.
|
2 weeks
|
|
Number of Participants Who Are Knowledgeable of Precautionary Measures to Prevent Infection
Time Frame: 4 months
|
4 months
|
|
|
Number of Participants With Positive SARs-CoV-2 Antigen Test Results
Time Frame: 4 months
|
4 months
|
|
|
Number of Healthcare Utilization Measures
Time Frame: 4 months
|
4 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Christoph Hornik, MD, Duke University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- Pro00108149
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.